Evommune, Inc. (NYSE:EVMN – Get Free Report) CFO Kyle Carver purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, July 8th. The stock was purchased at an average price of $13.26 per share, with a total value of $13,260.00. Following the transaction, the chief financial officer owned 60,335 shares of the company’s stock, valued at approximately $800,042.10. This represents a 1.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Kyle Carver also recently made the following trade(s):
- On Thursday, May 28th, Kyle Carver sold 18,175 shares of Evommune stock. The stock was sold at an average price of $22.84, for a total transaction of $415,117.00.
Evommune Stock Performance
NYSE EVMN traded down $0.28 during trading hours on Friday, reaching $13.23. The company’s stock had a trading volume of 585,866 shares, compared to its average volume of 1,374,484. The company’s 50-day moving average is $20.37 and its two-hundred day moving average is $22.01. The stock has a market cap of $476.40 million and a PE ratio of -1.39. Evommune, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $33.20.
Institutional Trading of Evommune
Several large investors have recently added to or reduced their stakes in the stock. Capricorn Fund Managers Ltd acquired a new position in Evommune in the 4th quarter worth $1,027,000. Sofinnova Investments Inc. acquired a new stake in shares of Evommune during the fourth quarter valued at about $2,625,000. NEXTBio Capital Management LP purchased a new stake in shares of Evommune during the fourth quarter worth about $3,908,000. Monashee Investment Management LLC purchased a new position in Evommune in the fourth quarter valued at about $3,137,000. Finally, EQT Fund Management S.a r.l. acquired a new stake in Evommune during the 4th quarter valued at approximately $84,395,000.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on EVMN shares. Raymond James Financial downgraded Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. William Blair cut Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Stifel Nicolaus assumed coverage on shares of Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 price target for the company. Oppenheimer began coverage on shares of Evommune in a research note on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Wall Street Zen cut Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.62.
Read Our Latest Stock Report on Evommune
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Featured Articles
- Five stocks we like better than Evommune
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
